Health · 1 sources covering this

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/d622a0b49f8709be8f794db4c4036e4d557724d5"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer"></iframe>

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

How 1 sources are covering this

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

More from Health

STAT+: Rising premiums, a sad Medicaid gathering, and a new fraud crackdown

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

STAT+: Five biotech updates to read after ESMO this weekend

STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

More from Health

STAT+: Rising premiums, a sad Medicaid gathering, and a new fraud crackdown

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

STAT+: Five biotech updates to read after ESMO this weekend

STAT+: Pharmalittle: We&#8217;re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more